Alka Chaubey - 02 Feb 2026 Form 4 Insider Report for Bionano Genomics, Inc. (BNGO)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: BNGO
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:18:34 UTC
Prior SEC filing: 12 Sep 2025
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan V. Dixon, Attorney-in-Fact

Key filing fact

Alka Chaubey filed Form 4 for Bionano Genomics, Inc. (BNGO) on 04 Feb 2026.

Key facts

This page summarizes Alka Chaubey's Form 4 filing for Bionano Genomics, Inc. (BNGO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:18.

Change

Previous filing in this sequence was filed on 12 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821605 Primary reporting owner

Chaubey Alka

Relationship: CHIEF MEDICAL OFFICER
Address: C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Jonathan V. Dixon, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNGO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +27,737
Change %
Price: $0.000000
Shares after: 27,737
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,737
Exercise price: $1.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.